Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The Eijkman Oxford Clinical Research Unit in Indonesia and Sumba Foundation collaborated with photographer Yoppy Pieter to express the human face of leprosy in Sumba, a remote island in eastern Indonesia. The project aimed to visualize the story of leprosy and raise awareness of this debilitating and heavily stigmatised disease

Leprosy patient showing hypopigmented skin lesions with loss of sensation © 2022 Elsevier Ltd
Agustinus developed six hypopigmented skin lesions with loss of sensation in the past five years. The lesions started on his chin and slowly extended to his arms and legs. He was diagnosed with multibacillary leprosy a year ago. In endemic settings, leprosy is diagnosed on the basis of the presence of at least one out of three cardinal signs: the presence of skin lesions with definite loss of sensation, a thickened or enlarged peripheral nerve, and a positive slit­ skin smear (or skin/nerve biopsy) with the demonstration of mycobacteria.

Leprosy impacts impoverished communities in low-income and middle-income countries (LMICs), with over 200,000 new cases recorded annually worldwide. This infectious disease is caused by Mycobacterium leprae or Mycobacterium lepromatosis and primarily affects the skin and peripheral nerves. Effective multidrug therapy is available, and, with early detection and treatment, leprosy is curable. Yet disease management can be complicated by immune-mediated reactions, which may cause irreversible nerve damage and lead to lifelong disabilities that are associated with stigmatisation and discrimination. Despite progress in the past few decades, the disease burden has stalled, with some countries not meeting WHO goals of interrupting transmission and reducing incidence.

The Eijkman Oxford Clinical Research Unit (EOCRU) in Indonesia and Sumba Foundation collaborated with photographer Yoppy Pieter to express the human face of leprosy in Sumba, a remote island in eastern Indonesia. The project aimed to visualise the story of leprosy and raise awareness of this debilitating and heavily stigmatised disease.

This photo is a part of the series “Picturing health: the burden of leprosy in eastern Indonesia” on The Lancet website

The full story is available on the OUCRU website

 

 

Similar stories

Watch our webinar - Radical cure of vivax malaria: can we do better?

The three presentations and expert discussion by Dr Rob Commons, Dr Alison Roth and Dr James Watson, chaired by Professor Sir Nicholas White (Mahidol Oxford Research Unit) and Dr Chau Nguyen Hoang (Oxford University Clinical Research Unit), are now available.

Shobhana Nagraj, Women in Science

Clinical Researcher Shobhana Nagraj, from the Health Systems Collaboratives in Oxford, tells us about the female role models who inspired her to follow her dreams

Multidisciplinary dengue forecasting project launches in Vietnam

DART (Dengue Advanced Readiness Tools), is a new project supported by Wellcome to use climate data to better predict and prepare for infectious diseases outbreaks.

OUCRU’s Photographer In Residence Featured In The Lancet’s Highlights 2022

Photographs have the power to inform and engage viewers. Earlier this year, The Lancet invited submissions for Highlights, the publication’s annual photography competition. Highlights 2022 featured 14 winning photographs telling stories from a wide variety of health-related topics that captured the world’s attention in 2022. One of the powerful images selected was from Pearl Gan, OUCRU’s Photographer in Residence.

Researchers call for antimicrobial resistance surveillance to be improved

The number of studies reporting antimicrobial resistance (AMR) data has increased in Africa, South and South East Asia according to new research in the International Journal of Infectious Diseases.

Are we getting tafenoquine dosing right?

Researchers analysing clinical trial data for the new antimalarial drug tafenoquine find that higher doses are needed to cure reliably vivax malaria infection.